Carvykti
by Johnson & Johnson
Carvykti is a one-time CAR-T cell therapy for relapsed or refractory multiple myeloma available through the Johnson & Johnson Patient Assistance Program.
Carvykti (ciltacabtagene autoleucel) is a BCMA-directed CAR-T (chimeric antigen receptor T-cell) therapy approved for adults with relapsed or refractory multiple myeloma who have received at least one prior line of therapy including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody. It is a personalized, one-time infusion therapy made from the patient's own T cells, which are genetically engineered to recognize and destroy myeloma cells expressing the BCMA protein. Carvykti is manufactured specifically for each patient and administered at certified treatment centers only.
Patient assistance programs
Johnson & Johnson Patient Assistance Program (J&J withMe)
Manufacturer PAP- Eligibility
- Uninsured or underinsured adults with a valid Carvykti prescription from a licensed U.S. oncologist at a certified treatment center who meet income requirements.
- Income limit
- Varies based on household size; generally ≤400% of Federal Poverty Level (FPL)
- Insurance
- Uninsured or underinsured
- How to apply
- Apply through ClariMeds — we handle all paperwork at no cost to you. Applications are submitted directly to J&J withMe on your behalf.
- Phone
- 1-800-652-6227
Need help applying?
ClariMeds handles the entire application process for you — for free. See if you qualify in minutes.
See If You Qualify — Free